Journal article icon

Journal article

In vivo effects of romidepsin on T-cell activation, apoptosis and function in the BCN02 HIV-1 kick&kill clinical trial

Abstract:

Romidepsin (RMD) is a well-characterized histone deacetylase inhibitor approved for the treatment of cutaneous T-cell lymphoma. in vitro and in vivo studies have demonstrated that it is able to induce HIV-1 gene expression in latently infected CD4+ T cells from HIV-1+ individuals on suppressive antiretroviral therapy. However, in vitro experiments suggested that RMD could also impair T-cell functionality, particularly of activated T cells. Thus, the usefulness of RMD in HIV-1 kick&kill strate...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.3389/fimmu.2020.00418

Authors


Expand authors...
Publisher:
Frontiers Media Publisher's website
Journal:
Frontiers in Immunology Journal website
Volume:
11
Article number:
418
Publication date:
2020-03-20
Acceptance date:
2020-02-24
DOI:
EISSN:
1664-3224
Pmid:
32265913
Language:
English
Keywords:
Pubs id:
1099545
Local pid:
pubs:1099545
Deposit date:
2020-06-02

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP